Analysts think DNLI stock price could increase by 114%
Jun 11, 2025, 11:26 AM
0.69%
What does DNLI do
Denali Therapeutics, a biopharmaceutical company based in South San Francisco, develops therapies for neurodegenerative diseases, with seven clinical candidates and ongoing studies for conditions like ALS and Parkinson's disease. The company went public on December 8, 2017, and has 375 employees.
17 analysts think DNLI stock price will increase by 113.96%. The current median analyst target is $32.64 compared to a current stock price of $15.26. The lowest analysts target is $26.26 and the highest analyst target is $47.25.
📡️ Health Care
Price Target
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
